Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and does not inhibit systemic T-cell activation

Dermatology. 1998;196(4):412-7. doi: 10.1159/000017934.

Abstract

Background: Psoriasis is a chronic T-cell-mediated inflammatory skin disease which can be treated with topical medication, phototherapy or systemic medication. A subgroup of psoriatic patients does not respond to monotherapy and needs combination therapy. We used low-dose narrow-band UVB phototherapy, combined with balneotherapy, short-contact anthralin, liquor carbonis detergens and calcipotriol for treatment of psoriatic patients in our day care centre.

Objective: Our purpose was to study the efficacy, induction of erythema and effect on systemic T-cell activation of this combination therapy.

Methods: Skin reflectance spectrophotometry was used to measure skin erythema. The Psoriasis Area and Severity Index (PASI) was used to evaluate psoriatic patients. Serum soluble IL-2 receptor (sIL2-R) levels were measured by an ELISA.

Results: The possible erythematogenic effect of low-dose narrow-band UVB irradiation was studied (skin reflectance spectrophotometer) in a control group of psoriatic patients (n = 11). No induction of skin erythema was seen. Subsequently, this low-dose irradiation regimen was used in combination with topical medication in 26 psoriatic patients. A 90% decrease in the PASI was seen after a mean number of 35 treatment sessions. Seventeen patients (65%) remained in remission during the following 6 months. Serum sIL-2R levels were elevated in all patients (mean 913 U/ml) and did not change during treatment.

Conclusion: Our data indicate that low-dose narrow-band UVB can be used successfully, in combination with topical treatment, in a day care setting to treat psoriatic patients. Since sIL-2R serum levels were not decreased, it can be speculated that this treatment does not induce systemic immunosuppression.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adolescent
  • Adult
  • Aged
  • Anthralin / adverse effects
  • Anthralin / therapeutic use
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use*
  • Balneology
  • Calcitriol / adverse effects
  • Calcitriol / analogs & derivatives
  • Calcitriol / therapeutic use
  • Combined Modality Therapy
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / therapeutic use
  • Dose-Response Relationship, Radiation
  • Erythema / etiology
  • Erythema / physiopathology
  • Humans
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / radiation effects
  • Middle Aged
  • Psoriasis / blood
  • Psoriasis / therapy*
  • Receptors, Interleukin-2 / blood
  • Severity of Illness Index
  • Solubility
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / radiation effects
  • Treatment Outcome
  • Ultraviolet Therapy* / adverse effects

Substances

  • Anti-Inflammatory Agents
  • Dermatologic Agents
  • Receptors, Interleukin-2
  • calcipotriene
  • Calcitriol
  • Anthralin